Anika Therapeutics, Inc. — FY2013 Form 10-K Summary
Business context and reporting period
Anika develops, manufactures and commercializes hyaluronic-acid-based products for tissue protection, healing and repair. Product categories include orthobiologics, dermal, surgical, ophthalmic and veterinary products. The filing covers the fiscal year ended December 31, 2013, with comparative results for 2012 and 2011. Anika operates primarily in the United States and through its wholly owned Italian subsidiary, Anika Therapeutics S.r.l.
Financial performance and condition
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Total revenue | $75.1 million | $71.4 million | Up 5% |
| Product revenue | $71.8 million | $68.0 million | Up 6% |
| Product gross profit | $49.0 million | $39.0 million | Up 26% |
| Product gross margin | 68% | 57% | Up 11 points |
| Income from operations | $32.6 million | $19.7 million | Up 65% |
| Net income | $20.6 million | $11.8 million | Up 75% |
| Diluted EPS | $1.39 | $0.82 | Up 70% |
| Cash flow from operations | $25.2 million | $10.5 million | Up $14.6 million |
| Cash and equivalents | $63.3 million | $44.1 million | Up $19.3 million |
| Working capital | $85.3 million | $62.9 million | Up $22.4 million |
| Long-term debt | None | $8.0 million | Debt retired |
Orthobiologics represented 78% of product revenue and increased 12% to $56.0 million. Dermal revenue increased 31% to $1.8 million, surgical revenue increased 8% to $5.4 million, and veterinary revenue increased 36% to $3.9 million. Ophthalmic revenue declined 47% to $4.7 million, primarily because Bausch & Lomb shifted manufacturing to another supplier.
Research and development expense increased 31% to $7.1 million, or approximately 9% of revenue. Selling, general and administrative expense decreased 12% to $12.9 million. The effective tax rate declined to 36.7% from 39.8%.
Material changes versus the prior comparable period
- Revenue growth was driven primarily by domestic and international ORTHOVISC sales, increased market penetration by Mitek, international viscosupplementation growth and geographic expansion.
- Product gross margin improved substantially due to elimination of duplicate manufacturing-facility costs, improved manufacturing efficiency and a greater mix of higher-margin orthobiologics products.
- The Italian tissue-engineering restructuring plan was completed. A $286,843 restructuring benefit was recorded in 2013, compared with approximately $2.5 million of restructuring and impairment charges in 2012.
- The company prepaid its remaining debt in November 2013. The total debt repayment during 2013 was $9.6 million, including the $8.4 million outstanding balance at the time of termination.
- Operating cash flow improved substantially, although inventory increased to $11.0 million from $8.3 million to support anticipated demand.
- Licensing, milestone and contract revenue was $3.3 million, broadly consistent with 2012. Recognition of the original $27 million JNJ Agreement upfront and milestone payments ended in 2013.
- Five customers accounted for approximately 79% of product revenue, including DePuy Mitek at 63% and Bausch & Lomb at 5%.
Guidance, outlook, commentary and unusual items
- Management expected orthobiologics, dermal advanced wound care and surgical revenue to increase in 2014. Veterinary revenue was expected to remain at a similar level.
- Bausch & Lomb revenue was expected to decline modestly in 2014 under lower contractual minimum volumes, and margins under the current agreement were expected to remain low.
- Research and development spending was expected to increase significantly, particularly for CINGAL, tissue-regenerative products, line extensions, new products and clinical trials.
- MONOVISC received U.S. FDA approval in February 2014, with commercial introduction planned for March 2014. The company expected additional payments and royalties from Mitek under the MONOVISC agreement.
- CINGAL entered a Phase III clinical trial in the second quarter of 2013. Regulatory approval, clinical success and commercial acceptance remain uncertain.
- The Genzyme patent litigation was dismissed with prejudice on March 10, 2014. Under the Mitek agreement, Anika is entitled to a $17.5 million milestone payment following the irrevocable resolution that permits MONOVISC commercialization without infringement.
- Anika believes existing cash and expected operating cash flow will fund working capital and capital expenditures for at least the next twelve months.
- At December 31, 2013, non-cancelable operating leases and purchase commitments totaled approximately $15.7 million, including $10.5 million of lease obligations.
Key risks and contingencies
- Dependence on regulatory approvals, clinical-trial outcomes, reimbursement decisions and continuing compliance with FDA, EMA, CE-mark and other foreign requirements.
- Concentration of customers and distribution partners, particularly DePuy Mitek, which represented 63% of product revenue.
- Competitive pressure from larger medical-device and pharmaceutical companies with greater resources.
- Manufacturing disruption and dependence on single or limited suppliers for certain raw materials, finished products and hyaluronic acid inputs.
- Potential volatility in demand, pricing, reimbursement, international economies, foreign exchange rates and Italian public-hospital collections.
- Potential impairment of goodwill, acquired intangible assets, inventory or other long-lived assets if performance or market conditions deteriorate.
- Product-liability, intellectual-property, regulatory and environmental risks. The company reported no material product-liability claims and maintained insurance of $5 million per occurrence and in the aggregate.
- The company reported no debt outstanding at year-end, but future financing could be required if product development, acquisitions or operating needs exceed internal resources.
Important facts for investors to verify
- Timing, sales ramp, reimbursement coverage, royalties and milestone payments associated with the U.S. launch of MONOVISC.
- Whether the $17.5 million Genzyme-related milestone payment was received and how it was recognized after the filing date.
- Sustainability of the 68% product gross margin after manufacturing efficiencies and favorable product mix effects.
- Customer concentration and the renewal or continuation of major Mitek, Bausch & Lomb and HYVISC-related arrangements.
- Progress, cost and regulatory status of CINGAL and other research and development programs.
- Inventory growth, receivable collections in Italy and any future write-downs or impairment charges.
- Future cash requirements, capital expenditures, lease obligations and the absence of a debt facility after the November 2013 repayment.
- Management’s forecasted 2014 operating-expense increases and the effect of the expiration of certain licensing revenue recognition in 2013.